Pregled bibliografske jedinice broj: 1257995
Risk Factors for Rivaroxaban-Related Bleeding Events-Possible Role of Pharmacogenetics: Case Series
Risk Factors for Rivaroxaban-Related Bleeding Events-Possible Role of Pharmacogenetics: Case Series // Pharmacy, 11 (2023), 1; 29, 19 doi:10.3390/pharmacy11010029 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1257995 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Risk Factors for Rivaroxaban-Related Bleeding
Events-Possible Role of Pharmacogenetics: Case
Series
Autori
Šimičević, Livija ; Slišković, Ana Marija ; Vrkić Kirhmajer, Majda ; Ganoci Lana ; Holik, Hrvoje ; Palić, Jozefina ; Samardžić, Jure ; Božina, Tamara
Kolaboracija
HRZZ-UIP-2020-02-8189
Izvornik
Pharmacy (2226-4787) 11
(2023), 1;
29, 19
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
drug safety ; interactions ; multidisciplinary ; pharmacogenetic ; risk factors ; rivaroxaban ; rivaroxaban-related bleeding
Sažetak
Non-vitamin K antagonist oral anticoagulants’ interindividual trough concentration variability affects efficacy and safety, especially in bleeding events. Rivaroxaban is metabolised via CYP3A4/5-, CYP2J2-, and CYP-independent mechanisms and is a substrate of two transporter proteins: ABCB1 (MDR1, P-glycoprotein) and ABCG2 (BCRP ; breast-cancer-resistance protein). The polymorphisms of these genes may possibly affect the pharmacokinetics of rivaroxaban and, consequently, its safety profile. Rivaroxaban variability may be associated with age, liver and kidney function, concomitant illness and therapy, and pharmacogenetic predisposition. This case series is the first, to our knowledge, that presents multiple risk factors for rivaroxaban- related bleeding (RRB) including age, renal function, concomitant diseases, concomitant treatment, and pharmacogenetic data. It presents patients with RRB, along with their complete clinical and pharmacogenetic data, as well as an evaluation of possible risk factors for RRB. Thirteen patients were carriers of ABCB1, ABCG2, CYP2J2, and/or CYP3A4/5 gene polymorphisms. Possible drug–drug interactions with increased bleeding risk were identified in nine patients. Six patients had eGFR <60 mL/min/1.73 m2. Our data suggest a possible role of multiple factors and their interactions in predicting RRB ; however, they also indicate the need for further comprehensive multidisciplinary research to enable safer use of this product based on a personalised approach.
Izvorni jezik
Engleski
Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti, Farmacija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
Napomena
This research is funded by the Croatian Science
Foundation. Project name and number:
Pharmacogenomics in Prediction of Cardiovascular
Drugs Adverse Reaction (PGx CardioDrug), HRZZ-UIP-
2020-02-8189
POVEZANOST RADA
Projekti:
HRZZ-UIP-2020-02-8189 - Uloga farmakogenomike u predviđanju nuspojava kardiovaskularnih lijekova (PGx-CardioDrug) (Božina, Tamara, HRZZ - 2020-02) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Opća bolnica "Dr. Josip Benčević",
Klinički bolnički centar Zagreb
Profili:
Lana Ganoci
(autor)
Ana Marija Slišković
(autor)
Jure Samardžić
(autor)
Tamara Božina
(autor)
Majda Vrkić Kirhmajer
(autor)
Jozefina Palić
(autor)
Hrvoje Holik
(autor)
LIVIJA ŠIMIČEVIĆ
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Emerging Sources Citation Index (ESCI)
- Scopus
Uključenost u ostale bibliografske baze podataka::
- PubMed
- DOAJ